Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis

Prokhorova T.A.

Mental Health Research Centre

Boksha I.S.

Research Centre of Mental Health

Savushkina O.K.

Mental Health Research Centre

Tereshkina E.B.

Mental Health Research Centre

Vorobyeva E.A.

Mental Health Research Centre

Pomytkin A.N.

Research Centre of Mental Health

Kaleda V.G.

Mental Health Research Centre

SPIN RSCI: 9035-3290
Scopus AuthorID: 56765570100
ResearcherID: K-5466-2013
ORCID: 0000-0002-1209-1443

Burbaeva G.Sh.

Mental Health Research Centre

Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis

Authors:

Prokhorova T.A., Boksha I.S., Savushkina O.K., Tereshkina E.B., Vorobyeva E.A., Pomytkin A.N., Kaleda V.G., Burbaeva G.Sh.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3): 44‑48

DOI: 10.17116/jnevro20161163144-48

Downloaded: 7

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Prokhorova TA, Boksha IS, Savushkina OK, et al. . Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3):44‑48. (In Russ.)
https://doi.org/10.17116/jnevro20161163144-48

Close metadata

Recommended articles:

Willingness to expend effort for rewards in individuals at clinical high-risk for psychosis: a relationship with the severity and stability of negative symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):109-115

The relationship between the functional state of the brain and clinical and constitutional factors in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):123-128

The multidirectional effects of thrombin and the possibility of their control in neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):42-48

A perspective on the application of CRISPR/CAS9 genome editing system to study of molecular-genetic basis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33

Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87

Cerebral hemodynamic disorders in patients with schizophrenia with concomitant metabolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85

Clinical and psychopathological characteristics of patients with late-onset schizophrenia and schizophrenia-like psychoses in clusters identified by biological parameters. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):137-144

Clinical and psychometric characteristics of cognitive and negative disorders in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):64-71

Controversial issues of diagnosis and theoretical concepts of schizophrenia in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):17-24

Psychological concepts — design of clinical models of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):25-31

Objective — to evaluation of glutamate dehydrogenase (GDH) enzymatic activity in platelets of patients with endogenous psychoses.

Material and methods. Enzymatic cectivity of GDH evaluated in 69 patients with schizophrenia (n=48) or schizoaffective disorder (n=21) in comparison with control group (n=34) and elucidation of possible link between their platelet GDH activity and clinical psychopathological condition.

Results and conclusion. Generally, GDH activity in patients before antipsychotic treatment was significantly lower, than in control group. Significant differences were revealed in GDH activity before the treatment between subgroups of patients with first episode psychosis (FEP, n=34), chronic patients (n=35), and control group (n=34), wherein GDH activity correlated with PANSS in FEP patients before the treatment course. No links were found in patients with chronic schizophrenia. Besides, significant links between GDH activity determined before the treatment course and PANSS scores after the treatment were found in FEP patients: the higher were levels of platelet GDH activity in FEP patients, the lower were their PANSS scores after the treatment.

Conclusion. Initial (baseline) levels of platelet GDH activity can have value for prognosis of antipsychotic pharmacotherapy efficacy in patients with FEP.

Keywords:

glutamate dehydrogenase

platelets

schizophrenia

Authors:

Prokhorova T.A.

Mental Health Research Centre

Boksha I.S.

Research Centre of Mental Health

Savushkina O.K.

Mental Health Research Centre

Tereshkina E.B.

Mental Health Research Centre

Vorobyeva E.A.

Mental Health Research Centre

Pomytkin A.N.

Research Centre of Mental Health

Kaleda V.G.

Mental Health Research Centre

SPIN RSCI: 9035-3290
Scopus AuthorID: 56765570100
ResearcherID: K-5466-2013
ORCID: 0000-0002-1209-1443

Burbaeva G.Sh.

Mental Health Research Centre

List of references:

Egerton A, Fusar-Poli P, Stone JM. Glutamate and psychosis risk. Curr Pharm Des. 2012;18:4:466-478. doi:10.2174/138161212799316244.
Fuente-Sandova C, León-Ortiz P, Azcárraga M et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis. A longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry. 2013;70:10:1057-1066. doi:10.1001/jamapsychiatry.2013.289.
Merritt K, McGuire Ph, Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry. 2013. doi:10.3389/fpsyt.2013.00151.
Schobel SA, Chaudhury NH, Khan UA et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78:1:81-93. doi:10.1016/j.neuron.2013.02.011.
Bartha R, Williamson PC, Drost DJ. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54:959-965. doi:/10.1001/archpsyc.1997.01830220085012.
Gluck MR, Thomas RG, Davis KL et al. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002;159:1165-1173. doi:10.1176/appi.ajp.159.7.1165.
Krystal JH, Belger A, D’Souza DC et al. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology. 1999;21:143-157. doi:10.1016/s0893-133x(99)00102-5.
Tamminga CA, Frost DO. Changing concepts in the neurochemistry of schizophrenia. Am J Psychiatry. 2001;158:1365-1366. doi:10.1176/appi.ajp.158.9.1365.
Burbaeva GSh, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:675-680. doi:10.1016/s0278-5846(03)00078-2.
Бокша И.С. Взаимосвязь нейронов и глиальных клеток через метаболизм глутамата в мозге здоровых и психически больных людей. Биохимия. 2004;69:7:869-886. doi: 10.1023/b:biry.0000040194.97348.e7.
Бурбаева Г.Ш., Бокша И.С., Каледа В.Г., Бархатова А.Н., Турищева М.С., Омельченко М.А., Терешкина Е.Б., Савушкина О.К., Стародубцева Л.И., Прохорова Т.А., Воробьева Е.А. Белок, подобный глутаминсинтетазе, глутаматдегидрогеназа и цитохром с-оксидаза в тромбоцитах больных при первом психотическом приступе в связи с лечением. Журнал неврологии и психиатрии им С.С. Корсакова. 2011;111(9):61-66.
Berk M, Plein H, Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorder. Life Sci. 2000;66:25:2427-2432. doi:10.1016/s0024-3205(00)80002-8.
Kasatkina LA, Borisova TA. Glutamate release from platelets: exocytosis versus glutamate transporter reversal. Int J Biochem Cell Biol. 2013;45:11:2585-2595. doi:10.1016/j.biocel.2013.08.004.
Gluck MR, Thomas RG, Sivak MA. Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with sporadic amyotrophic lateral sclerosis — a study of potential pathogenetic mechanisms in neurodegenerative diseases. J Neural Transm. 2000;107:12:1437-1447. doi:10.1007/s007020070007.
Burbaeva GSh, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB, Boksha IS. Diversity of glutamate dehydrogenase in human brain. Progress in Neuro-Psychopharmacol. Biol Psychiatry. 2002;26:427-435. doi:10.1016/s0278-5846(01)00273-1.
Burbaeva GSh, Boksha IS, Tereshkina EB et al. Glutamate dehydrogenase immunoreactivity in platelets in schizophrenia. World J Biol Psychiatry. 2001;3:1:32.
Burbaeva GSh, Boksha IS, Tereshkina EB, Savushkina OK, Turishcheva MS, Starodubtseva LI, Brusov OS, Morozova MA. Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia. World J Biol Psychiatry. 2006;7:2:75-81. doi:10.1080/15622970510029957.
Fischer HF. L-glutamate dehydrogenase from bovine liver. In: Meister A (ed) Methods in enzymology. Academic Press New York. 1985;113:16-27. doi:10.1016/s0076-6879(85)13006-5.

Close metadata